CGEN

Compugen Ltd. · NASDAQ · Healthcare · USD · 20-F for 2025, filed 2026-03-02

Figures on this page computed 2026-11-08 12:32 UTC

Last close

1.96USD

Market data, 2026-11-06

Except where said otherwise: 20-F for 2025, filed 2026-03-02

5.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
- computed
- 20-F for 2025, filed 2026-03-02
The filing itself
207.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
The filing itself
48.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
The filing itself
43.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
The filing itself
0.03Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

3.46x

-1.65x

-2.30x

1.64x

0.47x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 20-F for 2025, filed 2026-03-02

Sales3.46x
Its own average over 8 years, 21.0M.
Profit-1.65x
Its own average over 10 years, -21.4M.
Free cash flow-2.30x
Its own average over 10 years, -13.6M.
Debt1.64x
Its own average over 4 years, 1.8M.
Price0.47x
Its own average over 11 years, 4. Market data, 2026-11-06

Free cash flow is furthest from its own average, at -2.30 times.

Sales is 3.46 times its own 8-year average; Profit is -1.65 times its own 10-year average; Free cash flow is -2.30 times its own 10-year average; Debt is 1.64 times its own 4-year average; Price is 0.47 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 20-F for 2025, filed 2026-03-02

Sales against its own 8-year average3.46
Source
filed
Statement
income
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
The filing itself
Profit against its own 10-year average-1.65
Source
filed
Statement
income
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
The filing itself
Free cash flow against its own 10-year average-2.30
Source
filed
Statement
income
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
The filing itself
Debt against its own 4-year average1.64
Source
filed
Statement
income
Fiscal year
2025
Accession
0001178913-26-000663
Reported in
USD
The filing itself
Price against its own 11-year average0.47Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD